Source-grounded facts extracted from Definitive Healthcare Corp.'s SEC 8-K filings across all families, newest first. Each cites a verbatim SEC excerpt.
Definitive Healthcare Corp. shareholders approved Advisory vote on the compensation of the Company's named executive officers at the 2026-06-04 meeting.
“Proposal 4 – Advisory Vote on Executive Compensation The stockholders approved, on an advisory basis, the compensation of the Company’s named executive officers as disclosed in the Proxy Statement. The results of such vote were: For Against Abstain Broker Non-Votes 108,811,271 12,680,719 19,223 10,023,267”
Definitive Healthcare Corp. shareholders approved Approval of an amendment to the Definitive Healthcare Corp. 2021 Equity Incentive Plan to increase the number of shares of Class A common stock available for grant by 15,000,000 at the 2026-06-04 meeting.
“Proposal 3 – Share Increase Proposal The stockholders approved an amendment to the 2021 Plan, to increase the number of shares of Common Stock that we will have authority to grant under the 2021 Plan by 15,000,000 from 30,972,789 to 45,972,789. The results of such vote were: For Against Abstain Broker Non-Votes 105,140,642 16,351,580 18,991 10,023,267”
Definitive Healthcare Corp. shareholders approved Ratification of the appointment of Deloitte & Touche LLP as the Company's independent registered public accounting firm for the year ending December 31, 2026 at the 2026-06-04 meeting.
“Proposal 2 – Ratification of Selection of Independent Public Registered Accounting Firm The stockholders ratified the appointment of Deloitte & Touche LLP as the Company’s independent registered public accounting firm for the year ending December 31, 2026. The results of such vote were: For Against Abstain 130,745,809 726,699 61,972”
Definitive Healthcare Corp. shareholders approved Election of each of the nominees for Class II directors at the 2026-06-04 meeting.
“Proposal 1 – Election of Directors The stockholders elected each of the three nominees named below as Class II directors to serve until the 2029 annual meeting of stockholders and until their successors are duly elected and qualified. The results of such vote were: Director Nominee For Withheld Broker Non-Votes Chris Egan 115,632,170 5,879,043 10,023,267 Sastry Chilukuri 114,385,076 7,126,137 10,023,267 Samuel A. Hamood 118,977,114 2,534,099 10,023,267”
Definitive Healthcare Corp. reported Q1 2026 results: revenue $55.9 million, net income $(192.4) million.
“First Quarter 2026 Financial Highlights: • Revenue was $55.9 million, a decrease of 6% from $59.2 million in Q1 2025. • Net Loss , inclusive of goodwill impairment charges of $197.2 million, was $(192.4) million, or (344)% of revenue, compared to $(155.1) million in Q1 2025, inclusive of goodwill impairment charges of $176.5 million, or (262)% of revenue.”
Definitive Healthcare Corp. terminated Nominating Agreement with SE VII DHC AIV, L.P. (effective 2026-04-03).
“the Company and Spectrum entered into a termination agreement that permanently and irrevocably terminated the Nominating Agreement in its entirety.”
Richard Booth departed as Chief Financial Officer at Definitive Healthcare Corp..
“The Company previously announced that Richard Booth, the Company’s current CFO, would be departing the Company effective June 1, 2025.”
Casey Heller was appointed as Chief Financial Officer at Definitive Healthcare Corp..
“On February 24, 2025, the Board of Directors (the “Board”) of the Company appointed Casey Heller to the position of Chief Financial Officer (“CFO”) effective June 2, 2025.”
Richard Booth departed as Chief Financial Officer at Definitive Healthcare Corp..
“Richard Booth, the Company’s Chief Financial Officer, and the Company agreed that Mr. Booth will be leaving the Company effective June 1, 2025.”
Kate Shamsuddin Jensen changed role as Chief Operating Officer at Definitive Healthcare Corp..
“On September 29, 2024, the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”) promoted Kate Shamsuddin Jensen, the Company’s current Chief Strategy Officer, to the role of Chief Operating Officer, effective as of October 1, 2024 (the “Effective Date”).”
Carrie Lazorchak resigned as Chief Revenue Officer at Definitive Healthcare Corp..
“On July 24, 2024, Carrie Lazorchak, the Chief Revenue Officer of the Company, provided the Company with notice of her resignation, effective August 2, 2024.”
Jason Krantz departed as Interim Chief Executive Officer at Definitive Healthcare Corp..
“Effective on the Start Date, Jason Krantz, the Company’s founder, Executive Chairman of the Board and current Interim CEO will step down from his role as Interim CEO and continue to serve as Executive Chairman of the Board.”
Kevin Coop was appointed as Chief Executive Officer at Definitive Healthcare Corp..
“On May 20, 2024, the Board of Directors (the “Board”) of Definitive Healthcare Corp. (the “Company”) appointed Kevin Coop to the position of Chief Executive Officer (“CEO”) and as a member of the Board, each effective June 24, 2024 (the “Start Date”).”
Definitive Healthcare Corp. reported first quarter ended March 31, 2024 results: revenue $63.5 million, net income $(12.7) million.
“EX-99.1 (EX-99.1) --- EX-99.1 Exhibit 99.1 Definitive Healthcare Reports Financial Results for First Quarter Fiscal Year 2024 First quarter revenue grew 7% year-over-year to $63.5 million Framingham, MA (May 7, 2024) – Definitive Healthcare Corp. (“Definitive Healthcare” or the “Company”) (Nasdaq: DH), an industry leader in healthcare commercial intelligence,”
Facts are extracted by an LLM and gated to those whose source quote is present verbatim in the filing text. Coverage is best-effort while backfill and monitoring mature; this is not yet a full-market index. See methodology.